메뉴 건너뛰기




Volumn 4, Issue 1, 2016, Pages

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

Author keywords

Cardiomyopathy; Checkpoint inhibitor; Immune related adverse events; Immunotherapy; Ipilimumab; Melanoma; Myocarditis; Nivolumab; Pembrolizumab

Indexed keywords

CARVEDILOL; CORTICOSTEROID; CREATINE KINASE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FUROSEMIDE; IPILIMUMAB; LEVOTHYROXINE; METHYLPREDNISOLONE; METOPROLOL; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; RAMIPRIL; SPIRONOLACTONE; TROPONIN;

EID: 84997633422     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-016-0152-y     Document Type: Article
Times cited : (413)

References (36)
  • 2
    • 79959772576 scopus 로고    scopus 로고
    • Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
    • Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517-26.
    • (2011) N Engl J Med , vol.364 , pp. 2517-2526
    • Robert, C.1    Thomas, L.2    Bondarenko, I.3    O'Day, S.4    Weber, J.5    Garbe, C.6
  • 3
    • 84898973055 scopus 로고    scopus 로고
    • Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
    • Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020-30.
    • (2014) J Clin Oncol , vol.32 , pp. 1020-1030
    • Topalian, S.L.1    Sznol, M.2    McDermott, D.F.3    Kluger, H.M.4    Carvajal, R.D.5    Sharfman, W.H.6
  • 5
    • 84879759020 scopus 로고    scopus 로고
    • Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma
    • Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134-44.
    • (2013) N Engl J Med , vol.369 , pp. 134-144
    • Hamid, O.1    Robert, C.2    Daud, A.3    Hodi, F.S.4    Hwu, W.J.5    Kefford, R.6
  • 7
    • 84885172487 scopus 로고    scopus 로고
    • Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience
    • Luke JJ, Callahan MK, Postow MA, Romano E, Ramaiya N, Bluth M, et al. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer. 2013;119:3687-95.
    • (2013) Cancer , vol.119 , pp. 3687-3695
    • Luke, J.J.1    Callahan, M.K.2    Postow, M.A.3    Romano, E.4    Ramaiya, N.5    Bluth, M.6
  • 8
    • 84924543977 scopus 로고    scopus 로고
    • Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma
    • Zimmer L, Vaubel J, Mohr P, Hauschild A, Utikal J, Simon J, et al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma. PLoS One. 2015;10:e0118564.
    • (2015) PLoS One , vol.10
    • Zimmer, L.1    Vaubel, J.2    Mohr, P.3    Hauschild, A.4    Utikal, J.5    Simon, J.6
  • 9
    • 84971362913 scopus 로고    scopus 로고
    • Efficacy and safety of nivolumab (NIVO) monotherapy in the treatment of advanced mucosal melanoma
    • Larkin J, D'Angelo S, Sosman JA, Lebbe C, Brady B, Neyns B, et al. Efficacy and safety of nivolumab (NIVO) monotherapy in the treatment of advanced mucosal melanoma. Pigment Cell Melanoma Res. 2016;28:789.
    • (2016) Pigment Cell Melanoma Res , vol.28 , pp. 789
    • Larkin, J.1    D'Angelo, S.2    Sosman, J.A.3    Lebbe, C.4    Brady, B.5    Neyns, B.6
  • 10
    • 84907996539 scopus 로고    scopus 로고
    • Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis
    • Min L, Hodi FS. Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis. Cancer Immunol Res. 2014;2:15-8.
    • (2014) Cancer Immunol Res , vol.2 , pp. 15-18
    • Min, L.1    Hodi, F.S.2
  • 11
    • 84859393995 scopus 로고    scopus 로고
    • CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma
    • Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012;18:2039-47.
    • (2012) Clin Cancer Res , vol.18 , pp. 2039-2047
    • Prieto, P.A.1    Yang, J.C.2    Sherry, R.M.3    Hughes, M.S.4    Kammula, U.S.5    White, D.E.6
  • 12
    • 84886943622 scopus 로고    scopus 로고
    • Re-orienting the immune system: Durable tumor regression and successful re-induction therapy using anti-PD1 antibodies
    • Lipson EJ. Re-orienting the immune system: Durable tumor regression and successful re-induction therapy using anti-PD1 antibodies. Oncoimmunology. 2013;2:e23661.
    • (2013) Oncoimmunology , vol.2
    • Lipson, E.J.1
  • 13
    • 84856014065 scopus 로고    scopus 로고
    • Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer
    • Graziani G, Tentori L, Navarra P. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer. Pharmacol Res. 2012;65:9-22.
    • (2012) Pharmacol Res , vol.65 , pp. 9-22
    • Graziani, G.1    Tentori, L.2    Navarra, P.3
  • 14
    • 84908354848 scopus 로고    scopus 로고
    • Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
    • Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384:1109-17.
    • (2014) Lancet , vol.384 , pp. 1109-1117
    • Robert, C.1    Ribas, A.2    Wolchok, J.D.3    Hodi, F.S.4    Hamid, O.5    Kefford, R.6
  • 15
    • 84869455987 scopus 로고    scopus 로고
    • Anti-cytotoxic T-cell lymphocyte antigen-4-induced regression of spinal cord metastases in association with renal failure, atypical pneumonia, vision loss, and hearing loss
    • Voskens C, Cavallaro A, Erdmann M, Dippel O, Kaempgen E, Schuler G, et al. Anti-cytotoxic T-cell lymphocyte antigen-4-induced regression of spinal cord metastases in association with renal failure, atypical pneumonia, vision loss, and hearing loss. J Clin Oncol. 2012;30:e356-7.
    • (2012) J Clin Oncol , vol.30
    • Voskens, C.1    Cavallaro, A.2    Erdmann, M.3    Dippel, O.4    Kaempgen, E.5    Schuler, G.6
  • 16
    • 67650491041 scopus 로고    scopus 로고
    • Anti-CTLA4 antibody-induced lupus nephritis
    • Fadel F, El KK, Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med. 2009;361:211-2.
    • (2009) N Engl J Med , vol.361 , pp. 211-212
    • Fadel, F.1    El, K.K.2    Knebelmann, B.3
  • 17
    • 68349092608 scopus 로고    scopus 로고
    • Autoimmune inflammatory myopathy after treatment with ipilimumab
    • Hunter G, Voll C, Robinson CA. Autoimmune inflammatory myopathy after treatment with ipilimumab. Can J Neurol Sci. 2009;36:518-20.
    • (2009) Can J Neurol Sci , vol.36 , pp. 518-520
    • Hunter, G.1    Voll, C.2    Robinson, C.A.3
  • 19
    • 79953300714 scopus 로고    scopus 로고
    • Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient
    • Wilgenhof S, Neyns B. Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Ann Oncol. 2011;22:991-3.
    • (2011) Ann Oncol , vol.22 , pp. 991-993
    • Wilgenhof, S.1    Neyns, B.2
  • 20
    • 27844458057 scopus 로고    scopus 로고
    • Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study
    • Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. 2005;12:1005-16.
    • (2005) Ann Surg Oncol , vol.12 , pp. 1005-1016
    • Maker, A.V.1    Phan, G.Q.2    Attia, P.3    Yang, J.C.4    Sherry, R.M.5    Topalian, S.L.6
  • 22
    • 84917708727 scopus 로고    scopus 로고
    • Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma
    • Chan MM, Kefford RF, Carlino M, Clements A, Manolios N. Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma. J Immunother. 2015;38:37-9.
    • (2015) J Immunother , vol.38 , pp. 37-39
    • Chan, M.M.1    Kefford, R.F.2    Carlino, M.3    Clements, A.4    Manolios, N.5
  • 23
    • 84997827416 scopus 로고    scopus 로고
    • Neurological, respiratory, musculoskeletal, cardiac and ocular side effects of anti-PD-1 therapy.
    • in press).
    • Zimmer L, Goldinger SM, Hofmann L., Loquai C, Ugurel S, Thomas I, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side effects of anti-PD-1 therapy. Eur J Cancer (in press).
    • Eur J Cancer
    • Zimmer, L.1    Goldinger, S.M.2    Hofmann, L.3    Loquai, C.4    Ugurel, S.5    Thomas, I.6
  • 24
    • 84872339660 scopus 로고    scopus 로고
    • The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network
    • Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One. 2013;8:e53745.
    • (2013) PLoS One , vol.8
    • Voskens, C.J.1    Goldinger, S.M.2    Loquai, C.3    Robert, C.4    Kaehler, K.C.5    Berking, C.6
  • 25
    • 84980509873 scopus 로고    scopus 로고
    • Late onset ipilimumab-induced pericarditis and pericardial effusion: a rare but life threatening complication
    • Yun S, Vincelette ND, Mansour I, Hariri D, Motamed S. Late onset ipilimumab-induced pericarditis and pericardial effusion: a rare but life threatening complication. Case Rep Oncol Med. 2015;2015:794842.
    • (2015) Case Rep Oncol Med , vol.2015 , pp. 794842
    • Yun, S.1    Vincelette, N.D.2    Mansour, I.3    Hariri, D.4    Motamed, S.5
  • 26
    • 84977156516 scopus 로고    scopus 로고
    • Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome
    • Geisler BP, Raad RA, Esaian D, Sharon E, Schwartz DR. Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome. J Immunother Cancer. 2015;3:4.
    • (2015) J Immunother Cancer , vol.3 , pp. 4
    • Geisler, B.P.1    Raad, R.A.2    Esaian, D.3    Sharon, E.4    Schwartz, D.R.5
  • 27
    • 84997637224 scopus 로고    scopus 로고
    • Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma
    • Laubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer. 2015;3:11.
    • (2015) J Immunother Cancer , vol.3 , pp. 11
    • Laubli, H.1    Balmelli, C.2    Bossard, M.3    Pfister, O.4    Glatz, K.5    Zippelius, A.6
  • 28
    • 84861109547 scopus 로고    scopus 로고
    • PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis
    • Tarrio ML, Grabie N, Bu DX, Sharpe AH, Lichtman AH. PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J Immunol. 2012;188:4876-84.
    • (2012) J Immunol , vol.188 , pp. 4876-4884
    • Tarrio, M.L.1    Grabie, N.2    Bu, D.X.3    Sharpe, A.H.4    Lichtman, A.H.5
  • 29
    • 53149113444 scopus 로고    scopus 로고
    • Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice
    • Lucas JA, Menke J, Rabacal WA, Schoen FJ, Sharpe AH, Kelley VR. Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice. J Immunol. 2008;181:2513-21.
    • (2008) J Immunol , vol.181 , pp. 2513-2521
    • Lucas, J.A.1    Menke, J.2    Rabacal, W.A.3    Schoen, F.J.4    Sharpe, A.H.5    Kelley, V.R.6
  • 30
    • 77954019731 scopus 로고    scopus 로고
    • PD-1 deficiency results in the development of fatal myocarditis in MRL mice
    • Wang J, Okazaki IM, Yoshida T, Chikuma S, Kato Y, Nakaki F, et al. PD-1 deficiency results in the development of fatal myocarditis in MRL mice. Int Immunol. 2010;22:443-52.
    • (2010) Int Immunol , vol.22 , pp. 443-452
    • Wang, J.1    Okazaki, I.M.2    Yoshida, T.3    Chikuma, S.4    Kato, Y.5    Nakaki, F.6
  • 32
    • 10744220884 scopus 로고    scopus 로고
    • Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice
    • Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, Wang J, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med. 2003;9:1477-83.
    • (2003) Nat Med , vol.9 , pp. 1477-1483
    • Okazaki, T.1    Tanaka, Y.2    Nishio, R.3    Mitsuiye, T.4    Mizoguchi, A.5    Wang, J.6
  • 33
    • 0028867420 scopus 로고
    • Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
    • Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3:541-7.
    • (1995) Immunity , vol.3 , pp. 541-547
    • Tivol, E.A.1    Borriello, F.2    Schweitzer, A.N.3    Lynch, W.P.4    Bluestone, J.A.5    Sharpe, A.H.6
  • 34
    • 34548359396 scopus 로고    scopus 로고
    • CTLA-4 ablation and interleukin-12 driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes
    • Love VA, Grabie N, Duramad P, Stavrakis G, Sharpe A, Lichtman A. CTLA-4 ablation and interleukin-12 driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes. Circ Res. 2007;101:248-57.
    • (2007) Circ Res , vol.101 , pp. 248-257
    • Love, V.A.1    Grabie, N.2    Duramad, P.3    Stavrakis, G.4    Sharpe, A.5    Lichtman, A.6
  • 35
    • 84880730689 scopus 로고    scopus 로고
    • Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
    • Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013;122:863-71.
    • (2013) Blood , vol.122 , pp. 863-871
    • Linette, G.P.1    Stadtmauer, E.A.2    Maus, M.V.3    Rapoport, A.P.4    Levine, B.L.5    Emery, L.6
  • 36
    • 84899071058 scopus 로고    scopus 로고
    • Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody
    • 230ra45
    • Iwama S, De RA, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014;6:230ra45.
    • (2014) Sci Transl Med , vol.6
    • Iwama, S.1    De, R.A.2    Callahan, M.K.3    Slovin, S.F.4    Wolchok, J.D.5    Caturegli, P.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.